Call to arrange a consultation
+1 416 777 0888

Boehringer Ingelheim (Canada) Ltd et al. v Jamp Pharma Corportation

2022
T-2276-22
Pending
New PM(NOC) Regulations

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,696,558 and 2,752,435 (empagliflozin).

Counsel to: 
JAMP Pharma Corporation
here.